Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: A case series study

Chronobiology International

Volumn 24, Issue 3, 2007, Pages 521-537

  Willis, Gregory L ^a   Turner, E John D ^a  

^a Neurosciences Section   (Australia)

Author keywords

Bright light therapy; Depression; Insomnia; Melatonin; Parkinson's disease

Indexed keywords

AMANTAD; AMANTADINE; ANTIDEPRESSANT AGENT; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; DOSULEPIN; ELDOPRIL; LEVODOPA; MELATONIN; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE MESILATE; PROTHIADIN; SEDATIVE AGENT; SELEGILINE; SERTRALINE; SINAMET; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

ADULT; AGED; AGITATION; ARTICLE; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL FEATURE; DELUSION; DEPRESSION; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSKINESIA; EMOTIONAL STRESS; FEMALE; FLUORESCENT LIGHTING; HALLUCINATION; HUMAN; IMPOTENCE; INCREASED APPETITE; INSOMNIA; LIGHT EXPOSURE; MALE; MENTAL DISEASE; MOOD CHANGE; MORBIDITY; MOTOR PERFORMANCE; PARKINSON DISEASE; PATIENT COMPLIANCE; PHOTOTHERAPY; POLYPHARMACY; POSITIVE SYNDROME; RIGIDITY; SEBORRHEA; SLEEP; TREMOR;

AGED; AGED, 80 AND OVER; DELUSIONS; DEPRESSION; DOPAMINE; FEMALE; HALLUCINATIONS; HUMANS; HYPOKINESIA; INTERPERSONAL RELATIONS; MALE; MIDDLE AGED; MUSCLE RIGIDITY; PARKINSON DISEASE; PHOTOTHERAPY; PSYCHOMOTOR PERFORMANCE; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; TREMOR;

EID: 34347385604     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.1080/07420520701420717     Document Type: Article

References (80)

1. Andrade LAF, Lima JCG, Tufik S, Bertolucci PHF, Carlini EA. (1987). REM sleep deprivation in an experimental model of Parkinson's disease. Arq. Neuropsiquiatr. 45(3):224-230.
2. Antón-Tay F. (1974). Melatonin: effects on brain function. Adv. Biochem Pharmacol. 11:315-324.
3. Antón-Tay F, Diaz JL, Fernandez-Guardiola A. (1971). On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci. 10(Part 1):841-850.
4. Arieti S. (1954). The pineal gland in old age. J. Neuropathol. Exp. Neurol. 13:482-491.
5. Arnulf I, Konofal E, Merino-Andreu M, Hoveto JL, Mesnage V, Welter ML, Lacomblez L, Golmard JL, Derenne JP, Agid Y. (2002). Parkinson's disease and sleepiness; an integral part of PD. Neurology. 58:1019-1024.
6. Artemenko AR, Levin YI. (1996). Light therapy of patients with Parkinsonism. Zh. Nevropatol. Psikhiatr. Im. SS Korsakova. 96:63-66.
7. Benedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E. (2003). Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J. Clin. Psychiatry. 64:648-653.
8. Bertolucci PHF, Andrade LAF, Lima JGC, Carlini EA. (1987). Total sleep deprivation and Parkinson's disease. Arq. Neuropsychiatr. 45:224-230.
9. Bordet R, Devos D, Brique S, Touitou Y, Guieu JD, Libersa C, Dustee A. (2003). Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin. Neuropharmacol. 26:65-72.
10. Brainard GC, Lewy AJ, Menaker M, Fredrickson RH, Miller LS, Weleber RJ, Cassone V, Hudson D. (1988). Dose response relationship between light iridescence and the suppression of melatonin in human volunteers. Brain Res. 454:212-218.
11. Bruguerolle B, Simon N. (2002). Biological rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin. Neuropharmacol. 25:194-201.
12. Burton JL, Cartlidge M, Schuster S. (1970). Effect of L-Dopa on the seborrhea of Parkinsonism. Lancet 4:19-20.
13. Burton JL, Cartlidge M, Schuster S. (1973). Effect of L-Dopa on the seborrhea of Parkinsonism. Br. J. Dermatol. 88:475-479.
14. Burton S, Daya S, Potgeiter B. (1991). Melatonin modulates apomorphine-induced rotational behaviour. Experientia 47:466-469.
15. Catala MD, Canete-Nicolas C, Iradi A, Tarazona PJ, Tormos JM, Pascual-Leone A. (1997). Melatonin levels in Parkinson's disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp. Gerontol. 32:553-558.
16. Cotzias GC, Papavasiliou PS, Ginos J, Steck A, Düby S. (1971). Metabolic modification of Parkinson's disease and chronic manganese poisoning. Ann. Rev. Med. 22:305-326.
17. Daramola GF, Olowu AO. (1972). Physiological and radiological implications of a low incidence of pineal calcification in Nigeria. Neuroendocrinology 9:41-57.
18. Demet EM, Chicz-Demet A, Fallon JH, Sokolski KN. (1999). Sleep deprivation therapy in depressive illness and Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 23:753-784.
19. Deniker P, Ginistet D, Loo H. (1975). Psychotropic drugs and mechanisms of mood regulation. Encephale 1:359-362.
20. Douyon R, Serby M, Klutchko B, Rutrosen J. (1989). ECT and Parkinson's disease revisited: a naturalistic study. Am. J. Psychiatr. 146(11):1451-1455.
21. Duvoisin RC, Golbe LI, Lepore FE. (1987). Progressive subnuclear palsy. Can. J. Neurol. Sci. 14:547-554.
22. Feldman RG. (1985). Parkinson's disease: individualizing therapy. Hospital Practice 20:185, 80a-e, i,m, p, u.
23. Fertl E, Auff E, Dopplebauer A, Waldhauser F. (1991). Circadian secretion pattern of melatonin in Parkinson's disease. J. Neural. Transm. 3:41-47.
24. Fertl E, Auff E, Dopplebauer A, Waldhauser F. (1993). Circadian secretion pattern of melatonin in novo Parkinson's patient. Evidence for phase shifting properties of L-dopa. J. Neural Transm. 5:227-234.
25. Fonda D. (1985). Parkinson's disease in the elderly: psychiatric manifestations. Geriatrics 40:109-112.
26. Gerbaldo H, Cassady S, Maurer K, Pieschl D. (1997). The assessment of light intensity preference in psychiatric patients. Acta. Psychiatr Scand. 95:236-241.
27. Girotti F, Carella F, Grassi MP, Solveri P, Marano R, Caraceni T. (1986). Motor and cognitive performance of Parkinson's patients in the on and off phases of the disease. J. Neurol. Neurosurg Psychiatr. 49:657-660.
28. Hasegawa A, Ahtsubo K, Mori W. (1987). Pineal gland in old age; quantitative and qualitative morphological study of 168 human autopsies. Brain Res. 409:343-349.
29. Horne JA, Donlon J, Arendt J. (1991). Green light attenuates melatonin output and sleeplessness during sleep deprivation. Sleep. 14:233-240.
30. Jeanneau A. (1993). Electroconvulsive therapy in the treatment of Parkinson's disease. Encephale 19:573-578.
31. Karesek M. (1999). Melatonin in humans where we are 40 years after its discovery. Neurosci. Lett. 20:179-188.
32. Kendall B, Cavanagh N. (1986). Intracranial calcification in paediatric computed tomography. Neuroradiology 28:324-330.
33. Krahn LE, Gleber E Rummans TA, Pileggi TS, Lucas DL, Li H. (2000). The effects of electroconvulsive therapy on melatonin. JECT. 16:391-398.
34. Krstic R. (1986). Pineal calcification: its mechanism and significance. J Neural Transm. (Suppl. 21):415-432.
35. Kunz D, Bes F Schlattmann P, Herrmann WM. (1998). On pineal calcification and its relation to subjective sleep perception: a hypothesis driven pilot study. Psychiatr. Res. 82:187-191.
36. Kuzuhara S. (2001). Drug induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma. Neurol. 248(Suppl. 3):28-31.
37. Larsen TA, Calne S, Calne DB. (1984). Assessment of Parkinson's disease. Clin. Neuropharmacol. 7:165-169.
38. Lewy AJ, Wehr TZ, Goodwin FK, Newsome DA, Markey SP. (1980). Light suppresses melatonin secretion in humans. Science 210:1267-1269.
39. Likert RA. (1932). A technique for the measurements of attitudes. Arch. Psych. No. 140.
40. Maietta G, Rongioletti F, Rebora A. (1991). Seborrheic dermatitis and daylight. Acta Derm. Veneroel (Stock). 71:538-593.
41. Martiny K. (2004). Adjunctive bright light in non-seasonal major depression. Acta Psychiatr. Scand. Suppl. 425:7-28.
42. Mayo JC, Sainz RM, Uria H, Antolin I, Esteban MM, Rodriguez C. (1998). Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J. Pin. Res. 24:179-92.
43. Meco G, Bonifati V, Bedin L, Bellatreccia A, Vanacoe N, Franzese A. (1991). Relations between on-off phenomena and cognitive function in Parkinson's disease. Ital. J. Neurol. Sci. 12:57-62.
44. Okudera H, Hara H, Kobayashi S, Akada T, Shimizu K. (1986). Evaluation of the intracranial calcification associated with aging on computed tomography. Brain and Nerve. 38:129-133.
45. Okun MS, Watts RL. (2002). Depression associated with Parkinson's disease. Clinical factors and treatment. Neurology. 58(Suppl. 1):S63-S70.
46. Old V, Firm IN. (1974). Parameters of normality in a geriatric population. Arch. Int. Med. 132:101-132.
47. Papavasiliou PS, Cotzias GC, Düby SE, Steck AJ, Bell M, Lawrence WH. (1972). Melatonin and Parkinsonism. JAMA. 221(1):88-89.
48. Partinen M. (1997). Sleep disorders related to Parkinson's disease. J. Neurology. 224:S3-S6.
49. Patterson AJ, Vickers C. (1984). Sex and strain related effects of melatonin and 5-methoxytryptophol on open filed behaviour in paired mice. Behav. Brain. Res. 13:107-113.
50. Price LH, Spencer DD, Marek KL, Robbins RJ, Leranth C, Farhi A, Naftolin F, Roth RH, Bunney BS, Hoffer PB, Makuck R, Redmond DE. (1995). Psychiatric status after foetal mesencephalic tissue transplantation in Parkinson's disease. Biol. Psychiatr. 38:498-505.
51. Ralph CL. (1976). Correlations of melatonin content in pineal gland, blood and brain of some birds and mammals. Am. Zool. 16:35-43.
52. Reist C, Sokolski KN, Chen CC, Koskinas E, Demet EM. (1995). The effect of sleep deprivation on motor impairment and retinal adaptation in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatr. 19:445-454.
53. Reiter RJ. (1998). Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol. 56:359-384.
54. Rosenthal NE, Sack DA, Gillen JC, Lewy AJ, Goodwin FK, Davenport Y, Mueller PS, Newsome DA, Wehr TA. (1984). Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch. Gen. Psychiatr. 41:72-80.
55. Rosenthal NE, Jacobson FM, Sack DA, Arendt J, James SP, Parry BL, Wher TA. (1988). Atenolol in seasonal affective disorder: a test of the melatonin hypothesis. Am. J. Psychiatr. 145:52-56.
56. Roth W, Wurtman RJ, Altschule MD. (1962). Morphological changes in the pineal parenchyma cells exposed to continuous light or darkness. Endocrinology 71:888-892.
57. Sandyk R. (1990). Mechanisms of action of ECT in Parkinson' disease: possible role of pineal melatonin. Int. J. Neurosci. 50:83-94.
58. Sandyk R. (1992a). Weak magnetic fields in the treatment of Parkinson' disease with the "on-off" phenomenon. Int. J. Neurosci. 66:97-106.
59. Sandyk R. (1992b). Successful treatment of multiple sclerosis with magnetic fields. Int. J. Neurosci. 66:237-250.
60. Sartucci F, Orlandi G, Lucetti C, Bonuccelli U, Murri L, Orsini C, Porciatti V. (2003). Changes in pattern electroretinograms to equiluminate red-green and blue-yellow gratings in patients with early Parkinson's disease. J. Clin. Neurophysiol. 20:375-381.
61. Schnaberth G. (1986). Depression and Parkinson syndrome. Wein. Med. Wochenschr. 136(15-16):391-393.
62. Shaw KM. (1977). Hypothalamo-pituitary-adrenal function in Parkinsonian patients and patients treated with melatonin. Curr. Med. Res. Op. 4:743-746.
63. Shaw KM, Stern GM, Sandler M. (1973). Melatonin and Parkinsonism. Lancet 1:271.
64. Shaw KM, Stern GM, Sandler M. (1975). Melatonin and metatyrosine in the treatment of Parkinsonism. Adv. Neurol. 3:115.
65. The Parkinson Archive Treasures Pieno Parkinson, (1995). An international email list and website about Parkinson's disease. http://www.parkinsons- information-information-exchange-networkonline. com/. Accessed June 2006.
66. Toutiou Y, Smolensky MH, Portaluppi F. (2006). Ethics, standards, and procedures of animal and human chronobiology research. Chronobiol. Int. 23:1083-1096.
67. Verschoore M, Ortonne JP. (1993). Seborrheic dermatitis and daylight. Acta Derm. Venereol. 73:396.
68. Welker HA, Semm P, Willig RP, Commentz JC, Wiltschko W, Vollrath L. (1983). Effects of artificial magnetic field on serotonin-N-acetyltransferase activity and melatonin content of the rat pineal gland. Exp. Brain. Res. 50:426-432.
69. Willis GL. (2005). The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function. Behav. Brain. Res. 160:148-160.
70. Willis GL, Armstrong SM. (1998). Orphan neurones and amine access: the functional neuropathology of Parkinsonism and neuropsychiatric disease. Brain Res. Rev. 27:177-242.
71. Willis GL, Armstrong SM. (1999). A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol. Behav. 66:785-795.
72. Willis GL, Kennedy GA. (2004). The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease. Rev. Neurosci. 15:75-87.
73. Willis GL, Robertson AD. (2004). Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor. Pharmac. Biochem. Behav. 70:413-429.
74. Willis GL, Robertson AD. (2005). Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl, 1,2,3,6 tetrahydropyridine hydrochloride (MPTP) treated marmoset with the melatonin analogue ML-23. Pharmac. Biochem. Behav. 80:9-26.
75. Wright HR, Lack LC. (2001). Effect of light wavelength on suppression and phase delay of the melatonin rhythm. Chronobiol. Int. 18:801-808.
76. Wright HR, Lack LC, Partridge KJ. (2001). Light emitting diodes can be used to phase delay the melatonin rhythm. J. Pineal. Res. 31:350-355.
77. Wurtman RJ, Axelrod J. (1965). The formation metabolism and physiologic effects of melatonin in mammals. Prog. Brain. Res. 10:520-529.
78. Wurtman RJ, Axelrod J, Barchas JD. (1964). Age and enzyme activity in the human pineal. J. Clin. Endocrin. 24:299-301.
79. Zimmerman RA, Bilaniuk LT. (1982). Age related incidence of pineal calcification detected by computed tomography. Radiology. 142:659-662.
80. Zisapel N. (2001). Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting. Cell. Mol. Neurobiol. 21:605-616.